Sponsors (4)
The bill directs federal attention and modest funding toward earlier diagnosis, better care, and greater equity for women and girls with bleeding disorders, but it increases federal spending and risks implementation, capacity, and evaluation challenges that could delay or unevenly distribute benefits.
Women and girls with bleeding disorders will be diagnosed earlier and get access to specialized care, reducing complications and helping preserve fertility.
A federally coordinated assessment will produce actionable recommendations to improve diagnosis, care access, and inclusion of women and girls in bleeding-disorder research.
A national, evidence-based awareness campaign (with dedicated funding) will increase public and provider recognition of bleeding disorders, leading to earlier referrals and diagnoses.
Taxpayers and insurers will face increased federal and health-system costs from the campaign and expanded diagnosis/research activities (including the $50M authorized for the campaign), raising budgetary pressure.
The mandated review and recommendations do not themselves fund new services, so improvements may be delayed until Congress or agencies appropriate additional resources.
Expanded screening, referrals, and research demand could strain specialty centers and require workforce or capacity expansion, creating local access bottlenecks.
Based on analysis of 4 sections of legislative text.
Requires an HHS review of federal programs on bleeding disorders in women and funds a national education campaign with $10M/year authorized for FY2027–FY2031.
Official title: To provide for increased research and initiatives related to bleeding disorders in underserved populations, and for other purposes.
Introduced May 13, 2026 by Julie Johnson · Last progress May 13, 2026
Requires HHS to review federal programs, provider training, access to care, and clinical research inclusion for bleeding disorders in women and girls, and to publish a comprehensive public report within two years. Using that report, HHS must competitively award grants or contracts to run a nationwide, evidence-based education and awareness campaign to improve awareness, diagnosis, and treatment for women and girls with bleeding disorders, with culturally and linguistically appropriate outreach and evaluation; $10 million per year is authorized for FY2027–FY2031.